Insulet Newsroom

Insulet Analyst Ratings

BenzingaJun 10 13:42 ET

Analysts Offer Insights on Healthcare Companies: Insulet (PODD) and Ultragenyx Pharmaceutical (RARE)

TipRanksMay 30 23:24 ET

Insulet Analyst Ratings

BenzingaMay 30 06:11 ET

Citi Upgrades Edwards, Tandem; Cuts Nevro, Establishment Labs

Seeking AlphaMay 22 13:56 ET

Insulet's Strong Market Position and Financial Health Merit a Buy Rating Despite Legal Challenges

TipRanksMay 16 12:41 ET

Analysts Have Conflicting Sentiments on These Healthcare Companies: Mersana Therapeutics (MRSN), Insulet (PODD) and Crispr Therapeutics AG (CRSP)

TipRanksMay 14 05:45 ET

Insulet Analyst Ratings

BenzingaMay 13 14:04 ET

Insulet's Strong Financial Performance and Strategic Developments Merit a Buy Rating

TipRanksMay 13 11:30 ET

Insulet (PODD) Gets a Hold From Stifel Nicolaus

TipRanksMay 12 22:07 ET

Analysts Conflicted on These Healthcare Names: Insulet (PODD) and Progyny (PGNY)

TipRanksMay 12 21:25 ET

Bank of America Securities Reaffirms Their Buy Rating on Insulet (PODD)

TipRanksMay 10 11:20 ET

Insulet Analyst Ratings

BenzingaMay 10 09:21 ET

Insulet (PODD) Gets a Buy From Piper Sandler

TipRanksMay 10 08:05 ET

Stifel Adjusts Price Target on Insulet to $185 From $208

MT NewswiresMay 10 07:34 ET

Insulet's Upbeat Performance and Future Outlook Justify a Buy Rating

TipRanksMay 10 06:00 ET

Insulet Analyst Ratings

BenzingaMay 7 05:37 ET

Insulet's Market Dominance and Growth Catalysts Prompt 'Buy' Rating

TipRanksMay 7 05:31 ET

Wolfe Research Upgrades Insulet to Outperform From Peer Perform, Price Target Is $200

MT NewswiresMay 7 05:30 ET

Analysts Offer Insights on Healthcare Companies: Insulet (PODD), Biomea Fusion (BMEA) and Soleno Therapeutics (SLNO)

TipRanksMar 22 07:26 ET

Analysts Are Bullish on These Healthcare Stocks: Insulet (PODD), Annovis Bio (ANVS)

TipRanksMar 21 07:45 ET